MAFInotuzumab ozogamicin (Besponsa) Infusion 1 mg
Treatment of patients with relapsed or refractory CD22 positive B-precursor acute lymphoblastic leukemia (ALL) for:
– up to a maximum of three cycles for induction in a lifetime, and
– up to three additional cycles for consolidation in a lifetime in patients who achieve a complete response after induction.
Patients with Philadelphia chromosome positive disease must have previously received a tyrosine kinase inhibitor before receiving inotuzumab.
Complete response is defined as a patient who:
a) has 5% or less bone marrow blasts; and
b) has no evidence of disease; and
c) has platelet count of more than 50,000 per microlitre; and
d) has absolute neutrophil count of more than 500 per microlitre.